All Stories

  1. A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo

    Article • Brain Behavior and Immunity, May 2024, Elsevier

    Professor Mark Cragg

  2. Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges

    Article • Clinical Cancer Research, January 2024, American Association for Cancer Research (AACR)

    Professor Mark Cragg

  3. Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity

    Article • Molecular Therapy, December 2023, Elsevier

    Professor Mark Cragg

  4. A Single Bout of Exercise Enhances the Efficacy of Rituximab Against Autologous Chronic Lymphocytic Leukaemia B Cells Ex Vivo By Transiently Increasing Natural Killer Cell Frequency in Blood, and Simultaneously Mobilises CD5 +CD19 +CD20 + B Cell...

    Article • Blood, November 2023, American Society of Hematology

    Professor Mark Cragg

  5. Human leukocyte immunoglobulin-like receptors in health and disease

    Article • Frontiers in Immunology, November 2023, Frontiers

    Professor Mark Cragg

  6. Special Issue “Advances in Genome Regulation in Cancer”

    Article • International Journal of Molecular Sciences, September 2023, MDPI AG

    Professor Mark Cragg

  7. Low and Mighty: How Low-Affinity Antibodies Boost Cancer Immunotherapy

    Article • TheScienceBreaker, September 2023, Universite de Geneve

    Professor Mark Cragg

  8. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression

    Article • Leukemia, August 2023, Springer Science + Business Media

    Professor Mark Cragg

  9. Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy

    Article • Nature Immunology, July 2023, Springer Science + Business Media

    Professor Mark Cragg

  10. Soluble CTLA-4 raises the threshold for T-cell activation and modulates anti-tumour immunity

    Article • June 2023, Cold Spring Harbor Laboratory Press

    Professor Mark Cragg

  11. Co-Stimulatory TNFR Agonism for Cancer Immunotherapy: Past, Current, and Future Perspectives

    Article • Frontiers in Immunology, April 2023, Frontiers

    Professor Mark Cragg

  12. Development of C1q Affinity Chromatography for the Study of C1q–IgG Interactions

    Article • The Journal of Immunology, April 2023, The American Association of Immunologists

    Professor Mark Cragg

  13. The Role of Mitotic Slippage in Creating a “Female Pregnancy-like System” in a Single Polyploid Giant Cancer Cell

    Article • International Journal of Molecular Sciences, February 2023, MDPI AG

    Professor Mark Cragg

  14. Reducing affinity as a strategy to boost immunomodulatory antibody agonism

    Article • Nature, February 2023, Springer Science + Business Media

    Professor Mark Cragg

  15. Synthetic STING agonists elicit powerful vaccine adjuvancy providing robust central memory and anti-tumour effects

    Article • January 2023, Cold Spring Harbor Laboratory Press

    Professor Mark Cragg

  16. KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity

    Article • The Journal of Immunology, July 2022, The American Association of Immunologists

    Professor Mark Cragg

  17. Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility

    Article • Science Immunology, July 2022, American Association for the Advancement of Science

    Professor Mark Cragg

  18. FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms

    Article • Cell Reports, July 2022, Elsevier

    Professor Mark Cragg

  19. Paradoxes of cancer: Survival at the brink

    Article • Seminars in Cancer Biology, June 2022, Elsevier

    Professor Mark Cragg

  20. (SUMO)-wrestling with rituximab

    Article • Blood, May 2022, American Society of Hematology

    Professor Mark Cragg

  21. HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy

    Article • Journal of Experimental & Clinical Cancer Research, April 2022, Springer Science + Business Media

    Professor Mark Cragg

  22. Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering

    Article • Communications Biology, March 2022, Springer Science + Business Media

    Professor Mark Cragg

  23. Role of the Circadian Clock “Death-Loop” in the DNA Damage Response Underpinning Cancer Treatment Resistance

    Article • Cells, March 2022, MDPI AG

    Professor Mark Cragg

  24. Role of the circadian clock “Death-Loop” in the DNA damage response underpinning cancer treatment resistance

    Article • January 2022, Cold Spring Harbor Laboratory Press

    Professor Mark Cragg

  25. Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E

    Article • Frontiers in Oncology, December 2021, Frontiers

    Professor Mark Cragg

  26. Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?

    Article • Rheumatology, November 2021, Oxford University Press (OUP)

    Professor Mark Cragg

  27. Synergistic effect of non-neutralizing antibodies and interferon-γ for cross-protection against influenza

    Article • iScience, October 2021, Elsevier

    Professor Mark Cragg

  28. Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies

    Article • Cancers, September 2021, MDPI AG

    Professor Mark Cragg

  29. Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia

    Article • Nature Communications, September 2021, Springer Science + Business Media

    Professor Mark Cragg

  30. Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

    Article • Blood Advances, July 2021, American Society of Hematology

    Professor Mark Cragg

  31. Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

    Article • Blood Advances, July 2021, American Society of Hematology

    Professor Mark Cragg

  32. TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity

    Article • Communications Biology, June 2021, Springer Science + Business Media

    Professor Mark Cragg

  33. Activation of GABA(A) receptors inhibits T cell proliferation

    Article • PLoS ONE, May 2021, PLOS

    Professor Mark Cragg

  34. Replicative senescence dictates the emergence of disease-associated microglia and contributes to Aβ pathology

    Article • March 2021, Cold Spring Harbor Laboratory Press

    Professor Mark Cragg

  35. Developing a 3D B Cell Lymphoma Culture System to Model Antibody Therapy

    Article • Frontiers in Immunology, February 2021, Frontiers

    Professor Mark Cragg

  36. Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways

    Article • iScience, February 2021, Elsevier

    Professor Mark Cragg

  37. Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus

    Article • Biologicals, January 2021, Elsevier

    Professor Mark Cragg

  38. Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

    Article • International Immunopharmacology, January 2021, Elsevier

    Professor Mark Cragg

  39. Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies

    Article • Molecular Cancer Therapeutics, December 2020, American Association for Cancer Research (AACR)

    Professor Mark Cragg

  40. Domain binding and isotype dictate the activity of anti-human OX40 antibodies

    Article • Journal for ImmunoTherapy of Cancer, December 2020, BMJ

    Professor Mark Cragg

  41. Genetic dissection of a major haplotype associated with arthritis reveal FcγR2b and FcγR3 to act additively

    Article • European Journal of Immunology, November 2020, Wiley

    Docent Kutty Selva Nandakumar, Professor Mark Cragg

  42. Engineered antibodies to combat viral threats

    Article • Nature, November 2020, Springer Science + Business Media

    Professor Mark Cragg

  43. Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment

    Article • Antibodies, November 2020, MDPI AG

    Professor Mark Cragg

  44. Immune characterization of pre-clinical murine models of neuroblastoma

    Article • Scientific Reports, October 2020, Springer Science + Business Media

    Professor Mark Cragg

  45. LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation

    Article • JCI Insight, September 2020, American Society for Clinical Investigation

    Professor Mark Cragg

  46. VISTA deficiency protects from immune complex-mediated glomerulonephritis by inhibiting neutrophil activation

    Article • Journal of Autoimmunity, September 2020, Elsevier

    Professor Mark Cragg

  47. BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression

    Article • Blood Advances, July 2020, American Society of Hematology

    Professor Mark Cragg

  48. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma

    Article • Blood Advances, June 2020, American Society of Hematology

    Professor Mark Cragg

  49. FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion

    Article • Journal for ImmunoTherapy of Cancer, June 2020, BMJ

    Professor Mark Cragg

  50. Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity

    Article • Cancer Cell, June 2020, Elsevier

    Professor Mark Cragg

  51. Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergens

    Article • Journal of Allergy and Clinical Immunology, April 2020, Elsevier

    Professor Mark Cragg

  52. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial

    Article • Leukemia, February 2020, Springer Science + Business Media

    Professor Mark Cragg

  53. A Single Monoclonal Antibody against the Peanut Allergen Ara h 2 Protects against Systemic and Local Peanut Allergy

    Article • International Archives of Allergy and Immunology, January 2020, Karger Publishers

    Professor Mark Cragg

  54. Signaling through the Inhibitory Fc Receptor FcγRIIB Induces CD8+ T Cell Apoptosis to Limit T Cell Immunity

    Article • Immunity, January 2020, Elsevier

    Professor Mark Cragg

  55. Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells

    Article • Clinical Cancer Research, December 2019, American Association for Cancer Research (AACR)

    Professor Mark Cragg

  56. BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia

    Article • Leukemia, August 2019, Springer Science + Business Media

    Professor Mark Cragg

  57. Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression

    Article • Cancer Immunology Research, August 2019, American Association for Cancer Research (AACR)

    Professor Mark Cragg

  58. When Three Isn't a Crowd: A Digyny Concept for Treatment-Resistant, Near-Triploid Human Cancers

    Article • Genes, July 2019, MDPI AG

    Professor Mark Cragg

  59. Cartilage-binding antibodies induce pain through immune complex–mediated activation of neurons

    Article • The Journal of Experimental Medicine, June 2019, Rockefeller University Press

    Docent Kutty Selva Nandakumar, Professor Mark Cragg

  60. Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format

    Article • Frontiers in Immunology, March 2019, Frontiers

    Professor Mark Cragg

  61. The Cancer Aneuploidy Paradox: In the Light of Evolution

    Article • Genes, January 2019, MDPI AG

    Professor Mark Cragg

  62. The Cancer Aneuploidy Paradox: In the Light of Evolution

    Article • January 2019, MDPI AG

    Professor Mark Cragg

  63. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function

    Article • Immunity, November 2018, Elsevier

    Professor Mark Cragg

  64. An unexpected protective role of low-affinity allergen-specific IgG through the inhibitory receptor FcγRIIb

    Article • Journal of Allergy and Clinical Immunology, November 2018, Elsevier

    Professor Mark Cragg

  65. Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia

    Article • October 2018, Springer Science + Business Media

    Professor Mark Cragg

  66. Deleting Malignant B Cells With Second-Generation Anti-CD20 Antibodies

    Article • Journal of Clinical Oncology, August 2018, American Society of Clinical Oncology (ASCO)

    Professor Mark Cragg

  67. Evaluating Anti-CD32b F(ab) Conformation Using Molecular Dynamics and Small-Angle X-Ray Scattering

    Article • Biophysical Journal, July 2018, Elsevier

    Professor Mark Cragg

  68. Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics

    Article • Glycobiology, June 2018, Oxford University Press (OUP)

    Professor Mark Cragg

  69. UC-1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb-mediated target cell deletion

    Article • Scandinavian Journal of Immunology, May 2018, Wiley

    Adam Gadd, Professor Mark Cragg

  70. Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies

    Article • Cancer Cell, April 2018, Elsevier

    Professor Mark Cragg

  71. Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation

    Article • Molecular & Cellular Proteomics, April 2018, Elsevier

    Professor Mark Cragg

  72. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo

    Article • The Journal of Immunology, February 2018, The American Association of Immunologists

    Professor Mark Cragg

  73. New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcγRIIB (CD32B)

    Article • Journal of Leukocyte Biology, February 2018, Wiley

    Professor Mark Cragg

  74. Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking

    Article • Scientific Reports, February 2018, Springer Science + Business Media

    Professor Mark Cragg

  75. Detection of Experimental and Clinical Immune Complexes by Measuring SHIP-1 Recruitment to the Inhibitory FcγRIIB

    Article • The Journal of Immunology, January 2018, The American Association of Immunologists

    Professor Mark Cragg

  76. Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment

    Article • Cancer Cell, December 2017, Elsevier

    Professor Mark Cragg

  77. Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?

    Article • Frontiers in Immunology, October 2017, Frontiers

    Professor Mark Cragg

  78. Accelerated Senescence of Cancer Stem Cells: A Failure to Thrive or a Route to Survival?

    Article • August 2017, IntechOpen

    Professor Mark Cragg

  79. Lamin B1 regulates somatic mutations and progression of B-cell malignancies

    Article • Leukemia, August 2017, Springer Science + Business Media

    Professor Mark Cragg

  80. Anti-FcγRIIB (CD32) Antibodies Differentially Modulate Murine FVIII-Specific Recall Responsein vitro

    Article • Scandinavian Journal of Immunology, July 2017, Wiley

    Professor Mark Cragg

  81. TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb—Letter

    Article • Cancer Research, June 2017, American Association for Cancer Research (AACR)

    Professor Mark Cragg

  82. STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy

    Article • Cancer Research, May 2017, American Association for Cancer Research (AACR)

    Professor Mark Cragg

  83. Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering

    Article • BioDrugs, May 2017, Springer Science + Business Media

    Professor Mark Cragg

  84. Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity

    Article • British Journal of Haematology, April 2017, Wiley

    Professor Mark Cragg

  85. Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms

    Article • The Journal of Immunology, April 2017, The American Association of Immunologists

    Professor Mark Cragg

  86. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples

    Article • Rheumatology, April 2017, Oxford University Press (OUP)

    Professor Mark Cragg

  87. Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy

    Article • Cancer Research, March 2017, American Association for Cancer Research (AACR)

    Iva Trenevska, Professor Mark Cragg

  88. Lack of Fc Gamma Receptor IIIA Promotes Rather than Suppresses Humoral and Cellular Immune Responses after Mucosal or Parenteral Immunization with Antigen and Adjuvants

    Article • Scandinavian Journal of Immunology, March 2017, Wiley

    Professor Mark Cragg

  89. OX40: Structure and function – What questions remain?

    Article • Molecular Immunology, March 2017, Elsevier

    Professor Mark Cragg

  90. Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures

    Article • Molecular & Cellular Proteomics, January 2017, American Society for Biochemistry & Molecular Biology (ASBMB)

    Professor Mark Cragg

  91. Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain

    Article • Cell Reports, January 2017, Elsevier

    Professor Mark Cragg, Dr. Yajie Liang, Professor Zoltan Molnar

  92. IgG subclasses determine pathways of anaphylaxis in mice

    Article • Journal of Allergy and Clinical Immunology, January 2017, Elsevier

    Professor Mark Cragg

  93. Survival at the Brink

    Article • January 2017, Elsevier

    Professor Mark Cragg

  94. PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis

    Article • Leukemia, November 2016, Springer Science + Business Media

    Professor Mark Cragg

  95. Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study

    Article • British Journal of Cancer, September 2016, Nature

    Professor Mark Cragg

  96. Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?

    Article • Drug Discovery Today, August 2016, Elsevier

    Professor Mark Cragg

  97. FcγRIIB-Independent Mechanisms Controlling Membrane Localization of the Inhibitory Phosphatase SHIP in Human B Cells

    Article • The Journal of Immunology, July 2016, The American Association of Immunologists

    Professor Mark Cragg

  98. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

    Article • Leukemia, May 2016, Springer Science + Business Media

    Professor Mark Cragg

  99. Correction: Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus

    Article • PLoS ONE, March 2016, PLOS

    Dr Lee Machado, Professor Mark Cragg

  100. IL-4 enhances expression and function of surface IgM in CLL cells

    Article • Blood, March 2016, American Society of Hematology

    Professor Mark Cragg

  101. Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB

    Article • Journal of Clinical Immunology, February 2016, Springer Science + Business Media

    Professor Mark Cragg

  102. Erratum

    Article • Autophagy, February 2016, Taylor & Francis

    Dr Janos KristonVizi, Juan Segura-Aguilar, Professor Nektarios Tavernarakis, Dr Reinhard Dechant, Dr Vasilis J Promponas, Professor Marc Lecuit, Professor Paula I. Moreira, Professor Mark Cragg, Executive Director, The Hormel Institute Robert Clarke, Dr Eleonora García Véscovi, Professor Jean-François Beaulieu, Shile Huang, Maria João Sousa

  103. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Article • Autophagy, January 2016, Taylor & Francis

    Professor CIRO ISIDORO, Dr Akira Matsuura, Prof Hirokazu Arimoto, Professor Marc Diederich, Maria Vaccaro, Professor Abdel Halim Harrath, Professor Hyun Kyu Song, Dr Takeshi Noda, Dr Regina Menezes, Dr Janos KristonVizi, Cristina Muñoz-Pinedo, Professor Nektarios Tavernarakis, Juan Segura-Aguilar, Professor Marc Lecuit, Leonardo Travassos, Prof Robert Bryson-Richardson, Isabelle Dugail, PD Dipl.-Ing. Dr. techn. Werner J Kovacs, Dr Luca Galluzzi, Dr Reinhard Dechant, Dr. Sandra Moreno, Maurizio Molinari, Dr Vasilis J Promponas, Professor Günther Weindl, Dr Marc Etienne Poirot, Professor Paula I. Moreira, Maria João Sousa, Dr Janna Morrison, Professor Mark Cragg, Executive Director, The Hormel Institute Robert Clarke, Dr Eleonora García Véscovi, Paula Ludovico, Professor Jean-François Beaulieu, Shile Huang

  104. Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo

    Article • Blood, December 2015, American Society of Hematology

    Professor Mark Cragg

  105. Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus

    Article • PLoS ONE, November 2015, PLOS

    Professor Mark Cragg, Dr Lee Machado

  106. Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fc  Receptors

    Article • The Journal of Immunology, October 2015, The American Association of Immunologists

    Professor Mark Cragg

  107. Fcγ receptors: genetic variation, function, and disease

    Article • Immunological Reviews, October 2015, Wiley

    Professor Mark Cragg, Dr Lee Machado

  108. FcγR requirements leading to successful immunotherapy

    Article • Immunological Reviews, October 2015, Wiley

    Professor Mark Cragg

  109. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1

    Article • Leukemia, October 2015, Nature

    Professor Mark Cragg

  110. Abstract IA06: Designing immunostimulatory antibodies for cancer treatment

    Article • Cancer Immunology Research, October 2015, American Association for Cancer Research (AACR)

    Professor Mark Cragg

  111. Guidelines for antibody validation

    Article • mAbs, September 2015, Taylor & Francis

    Professor Alison H Banham, Professor Mark Cragg

  112. Antibody modulation: Limiting the efficacy of therapeutic antibodies

    Article • Pharmacological Research, September 2015, Elsevier

    Professor Mark Cragg

  113. Death by a thousand knives: Multiple BH3-only proteins are required for maximal apoptosis triggered through the BCR

    Article • Molecular & Cellular Oncology, August 2015, Taylor & Francis

    Professor Mark Cragg

  114. Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy

    Article • OncoImmunology, August 2015, Taylor & Francis

    Professor Mark Cragg

  115. BCR-signaling-induced cell death demonstrates dependency on multiple BH3-only proteins in a murine model of B-cell lymphoma

    Article • Cell Death and Differentiation, July 2015, Nature

    Professor Mark Cragg

  116. Role of stress-activated OCT4A in the cell fate decisions of embryonal carcinoma cells treated with etoposide

    Article • Cell Cycle, June 2015, Taylor & Francis

    Professor Mark Cragg

  117. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the E -TCL1 mouse model

    Article • Blood, May 2015, American Society of Hematology

    Professor Mark Cragg

  118. Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus

    Article • Arthritis & Rheumatology, May 2015, Wiley

    Professor Mark Cragg

  119. Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo

    Article • Cancer Cell, April 2015, Elsevier

    Professor Mark Cragg

  120. Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia

    Article • Leukemia, March 2015, Nature

    Professor Mark Cragg

  121. Rehabilitation or the death penalty: Autoimmune B cells in the dock

    Article • European Journal of Immunology, March 2015, Wiley

    Professor Mark Cragg

  122. STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage

    Article • Journal of Cell Science, March 2015, The Company of Biologists

    Professor Mark Cragg

  123. Role of the pro-survival molecule Bfl-1 in melanoma

    Article • The International Journal of Biochemistry & Cell Biology, February 2015, Elsevier

    Professor Mark Cragg

  124. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies

    Article • Blood, January 2015, American Society of Hematology

    Professor Mark Cragg

  125. Activatory and Inhibitory Fcγ Receptors Augment Rituximab-mediated Internalization of CD20 Independent of Signaling via the Cytoplasmic Domain

    Article • Journal of Biological Chemistry, January 2015, American Society for Biochemistry & Molecular Biology (ASBMB)

    Professor Mark Cragg

  126. Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies

    Article • Cancer Cell, January 2015, Elsevier

    Professor Mark Cragg

  127. The “virgin birth”, polyploidy, and the origin of cancer

    Article • Oncoscience, December 2014, Impact Journals, LLC

    Professor Mark Cragg

  128. Upregulation of Fc RIIb on monocytes is necessary to promote the superagonist activity of TGN1412

    Article • Blood, November 2014, American Society of Hematology

    Professor Mark Cragg

  129. Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98)

    Article • British Journal of Haematology, August 2014, Wiley

    Professor Mark Cragg

  130. Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization

    Article • The Journal of Immunology, July 2014, The American Association of Immunologists

    Professor Mark Cragg

  131. Development of immunomonitoring of antibody-dependent cellular cytotoxicity against neuroblastoma cells using whole blood

    Article • Cancer Immunology Immunotherapy, March 2014, Springer Science + Business Media

    Professor Mark Cragg

  132. Fcγ Receptor-Mediated Inflammation Inhibits Axon Regeneration

    Article • PLoS ONE, February 2014, PLOS

    Professor Mark Cragg

  133. CD20 and Its Antibodies: Past, Present, and Future

    Article • Forum on Immunopathological Diseases and Therapeutics, January 2014, Begell House

    Professor Mark Cragg

  134. FcγRIIB as a Key Determinant of Agonistic Antibody Efficacy

    Article • January 2014, Springer Science + Business Media

    Professor Mark Cragg

  135. Inhibitory Fc RIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

    Article • Blood, November 2013, American Society of Hematology

    Professor Mark Cragg

  136. Immunotherapy Targeting Inhibitory Fc  Receptor IIB (CD32b) in the Mouse Is Limited by Monoclonal Antibody Consumption and Receptor Internalization

    Article • The Journal of Immunology, September 2013, The American Association of Immunologists

    Professor Mark Cragg

  137. Novel antibodies targeting immune regulatory checkpoints for cancer therapy

    Article • British Journal of Clinical Pharmacology, July 2013, Wiley

    Professor Mark Cragg

  138. Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model

    Article • Clinical Cancer Research, May 2013, American Association for Cancer Research (AACR)

    Professor Mark Cragg

  139. FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs

    Article • Cancer Immunology Immunotherapy, March 2013, Springer Science + Business Media

    Professor Mark Cragg

  140. DNA damage causes TP53-dependent coupling of self-renewal and senescence pathways in embryonal carcinoma cells

    Article • Cell Cycle, February 2013, Taylor & Francis

    Professor Mark Cragg

  141. Expression of inhibitory Fc receptor (FcγRIIB) is a marker of poor response to rituximab monotherapy in follicular lymphoma

    Article • The Lancet, February 2013, Elsevier

    Professor Mark Cragg

  142. Overcoming Resistance to Therapeutic Antibodies by Targeting Fc Receptors

    Article • January 2013, Springer Science + Business Media

    Professor Mark Cragg

  143. Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal

    Article • Cancer Cell International, January 2013, Springer Science + Business Media

    Professor Mark Cragg

  144. Transforming Growth Factor-β Directly Induces p53-up-regulated Modulator of Apoptosis (PUMA) during the Rapid Induction of Apoptosis in Myc-driven B-cell Lymphomas

    Article • Journal of Biological Chemistry, December 2012, American Society for Biochemistry & Molecular Biology (ASBMB)

    Professor Mark Cragg

  145. Macroautophagy-aided elimination of chromatin

    Article • Autophagy, December 2012, Taylor & Francis

    Professor Mark Cragg

  146. CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737

    Article • Experimental Hematology, September 2012, Elsevier

    Professor Mark Cragg

  147. Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B)

    Article • European Journal of Immunology, July 2012, Wiley

    Professor Mark Cragg

  148. Role of STAT1 in the breast

    Article • JAK-STAT, July 2012, Taylor & Francis

    Professor Mark Cragg

  149. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

    Article • Blood, February 2012, American Society of Hematology

    Professor Mark Cragg

  150. Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation

    Article • Cell Biology International, August 2011, Wiley

    Professor Mark Cragg

  151. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

    Article • Blood, July 2011, American Society of Hematology

    Professor Mark Cragg

  152. CD20 antibodies: doing the time warp

    Article • Blood, July 2011, American Society of Hematology

    Professor Mark Cragg

  153. Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

    Article • The Journal of Immunology, July 2011, The American Association of Immunologists

    Professor Mark Cragg

  154. Tumor cell embryonality and the ploidy number 32n: Is it a developmental checkpoint?

    Article • Cell Cycle, June 2011, Taylor & Francis

    Professor Mark Cragg

  155. Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation

    Article • Cell Biology International, May 2011, Wiley

    Professor Mark Cragg

  156. Systemic Inflammation Modulates Fc Receptor Expression on Microglia during Chronic Neurodegeneration

    Article • The Journal of Immunology, May 2011, The American Association of Immunologists

    Professor Mark Cragg

  157. Family friction as ΔNp73 antagonises p73 and p53

    Article • The International Journal of Biochemistry & Cell Biology, April 2011, Elsevier

    Professor Mark Cragg

  158. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

    Article • Blood, March 2011, American Society of Hematology

    Professor Mark Cragg

  159. B cells—Masters of the immunoverse

    Article • The International Journal of Biochemistry & Cell Biology, March 2011, Elsevier

    Professor Mark Cragg

  160. Response: novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates

    Article • Blood, October 2010, American Society of Hematology

    Professor Mark Cragg

  161. Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim

    Article • Blood, September 2010, American Society of Hematology

    Professor Mark Cragg

  162. MOS, aneuploidy and the ploidy cycle of cancer cells

    Article • Oncogene, August 2010, Nature

    Professor Mark Cragg

  163. Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells

    Article • Experimental Cell Research, August 2010, Elsevier

    Professor Mark Cragg

  164. Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects

    Article • Journal of Immunological Methods, August 2010, Elsevier

    Professor Mark Cragg

  165. A role for neutrophils in rituximab therapy?

    Article • Leukemia Research, May 2010, Elsevier

    Professor Mark Cragg

  166. CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

    Article • Seminars in Hematology, April 2010, Elsevier

    Professor Mark Cragg

  167. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

    Article • Blood, March 2010, American Society of Hematology

    Professor Mark Cragg

  168. Regulating the genome surveillance system: miRNAs and the p53 super family

    Article • APOPTOSIS, January 2010, Springer Science + Business Media

    Professor Mark Cragg

  169. Complement: help or hindrance?

    Article • Blood, December 2009, American Society of Hematology

    Professor Mark Cragg

  170. Anti-CD20 monoclonal antibodies: historical and future perspectives

    Article • Haematologica, September 2009, Ferrata Storti Foundation (Haematologica)

    Professor Mark Cragg

  171. The role of meiotic cohesin REC8 in chromosome segregation in γ irradiation-induced endopolyploid tumour cells

    Article • Experimental Cell Research, September 2009, Elsevier

    Professor Mark Cragg

  172. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells

    Article • Journal of Clinical Investigation, July 2009, American Society for Clinical Investigation

    Professor Mark Cragg

  173. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

    Article • Nature Reviews Drug Discovery, April 2009, Nature

    Professor Mark Cragg

  174. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis

    Article • Cell Death and Differentiation, January 2009, Nature

    Professor Mark Cragg

  175. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

    Article • Blood, November 2008, American Society of Hematology

    Professor Mark Cragg

  176. Response: Superior B cell–depleting activity of type II anti-CD20 mAb is not due to activation of complement

    Article • Blood, November 2008, American Society of Hematology

    Professor Mark Cragg

  177. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

    Article • Journal of Clinical Investigation, November 2008, American Society for Clinical Investigation

    Professor Mark Cragg

  178. Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy

    Article • Blood, September 2008, American Society of Hematology

    Professor Mark Cragg

  179. Radiation Therapy with Tositumomab (B1) Anti-CD20 Monoclonal Antibody Initiates Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase-Dependent Cell Death that Overcomes Resistance to Apoptosis

    Article • Clinical Cancer Research, August 2008, American Association for Cancer Research (AACR)

    Professor Mark Cragg

  180. Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling

    Article • Journal of Biological Chemistry, April 2008, American Society for Biochemistry & Molecular Biology (ASBMB)

    Professor Mark Cragg

  181. The Potential Effect of Statins on Rituximab Immunotherapy

    Article • PLoS Medicine, March 2008, PLOS

    Professor Mark Cragg

  182. Life-Cycle Features of Tumour Cells

    Article • January 2008, Springer Science + Business Media

    Professor Mark Cragg

  183. Cancer: A matter of life cycle?

    Article • Cell Biology International, December 2007, Wiley

    Professor Mark Cragg

  184. Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics

    Article • PLoS Medicine, October 2007, PLOS

    Professor Mark Cragg

  185. Mechanisms of killing by anti-CD20 monoclonal antibodies

    Article • Molecular Immunology, September 2007, Elsevier

    Professor Mark Cragg

  186. Correction for Kuroda et al., Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic

    Article • Proceedings of the National Academy of Sciences, October 2006, Proceedings of the National Academy of Sciences

    Professor Mark Cragg

  187. Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic

    Article • Proceedings of the National Academy of Sciences, October 2006, Proceedings of the National Academy of Sciences

    Professor Mark Cragg

  188. Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe

    Article • BMC Cancer, January 2006, Springer Science + Business Media

    Professor Mark Cragg

  189. Mitotic catastrophe and endomitosis in tumour cells: An evolutionary key to a molecular solution

    Article • Cell Biology International, December 2005, Wiley

    Professor Mark Cragg

  190. Segregation of genomes in polyploid tumour cells following mitotic catastrophe

    Article • Cell Biology International, December 2005, Wiley

    Professor Mark Cragg

  191. Functional Analysis of HIV Type 1 Nef Reveals a Role for PAK2 as a Regulator of Cell Phenotype and Function in the Murine Dendritic Cell Line, DC2.4

    Article • The Journal of Immunology, November 2005, The American Association of Immunologists

    Professor Mark Cragg

  192. STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage

    Article • Journal of Cell Science, March 2005, The Company of Biologists

    Professor Mark Cragg

  193. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

    Article • Blood, September 2004, American Society of Hematology

    Professor Mark Cragg

  194. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells

    Article • Blood, June 2004, American Society of Hematology

    Professor Mark Cragg

  195. Apparent modulation of CD20 by rituximab: an alternative explanation

    Article • Blood, May 2004, American Society of Hematology

    Professor Mark Cragg

  196. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

    Article • Blood, April 2004, American Society of Hematology

    Professor Mark Cragg

  197. The Biology of CD20 and Its Potential as a Target for mAb Therapy

    Article • January 2004, Karger Publishers

    Professor Mark Cragg

  198. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy

    Article • Blood, October 2003, American Society of Hematology

    Professor Mark Cragg

  199. Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks

    Article • Journal of Cell Science, October 2003, The Company of Biologists

    Professor Mark Cragg

  200. Mechanisms of CD40 Signaling in the Immune System

    Article • January 2003, Elsevier

    Professor Mark Cragg

  201. The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis

    Article • Blood, October 2002, American Society of Hematology

    Professor Mark Cragg

  202. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

    Article • Blood, September 2002, American Society of Hematology

    Professor Mark Cragg

  203. Nuclear envelope-limited chromatin sheets are part of mitotic death

    Article • Histochemistry and Cell Biology, February 2002, Springer Science + Business Media

    Professor Mark Cragg

  204. Article • Cancer Cell International, January 2001, Springer Science + Business Media

    Professor Mark Cragg

  205. A New in Vivo and in Vitro B cell Lymphoma Model, π-BCL1

    Article • Cancer Biotherapy & Radiopharmaceuticals, December 2000, Mary Ann Liebert Inc

    Professor Mark Cragg

  206. Radioimmunotherapy in the π-BCL 1 B cell Lymphoma Model: Efficacy Depends on More Than Targeted Irradiation Alone

    Article • Cancer Biotherapy & Radiopharmaceuticals, December 2000, Mary Ann Liebert Inc

    Professor Mark Cragg

  207. POLYPLOID GIANT CELLS PROVIDE A SURVIVAL MECHANISM FOR p53 MUTANT CELLS AFTER DNA DAMAGE

    Article • Cell Biology International, September 2000, Wiley

    Professor Mark Cragg

  208. RELEASE OF MITOTIC DESCENDANTS BY GIANT CELLS FROM IRRADIATED BURKITT'S LYMPHOMA CELL LINES

    Article • Cell Biology International, September 2000, Wiley

    Professor Mark Cragg

  209. Complement mediated cell death is associated with DNA fragmentation

    Article • Cell Death and Differentiation, January 2000, Nature

    Professor Mark Cragg

  210. Signaling antibodies in cancer therapy

    Article • Current Opinion in Immunology, October 1999, Elsevier

    Professor Mark Cragg

  211. Molecular markers of B-cell lymphoma

    Article • Seminars in Cancer Biology, April 1999, Elsevier

    Professor Mark Cragg

  212. Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells

    Article • British Journal of Cancer, January 1999, Nature

    Professor Mark Cragg